Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Republic Services Inc. Common Stock (RSG) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance

Republic Services Inc. Common StockTrade
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Trade

Price performance (Past 24H)

Key statistics

Republic Services Inc. Common Stock vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Republic Services Inc. Common Stock trades at $226.9 (market cap $68.73B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $19.5 (market cap $59.39B). The key difference: Republic Services Inc. Common Stock is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.24%). Which is the better fit depends on your goals.

RSGTAK
Market Cap
$68.73B$59.39B
Volume
1,226,7774,676,421
Sector
IndustrialsHealth
52-Week High
$232.27$19.05
52-Week Low
$197.73$13.23
Enterprise Value
$82.91B$87.25B
Dividend Yield
1.19%3.24%
Typical Hold Time
—6 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Republic Services Inc. Common Stock

No Aura AI signal available yet.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

TAK trades at $18.52, down 0.86% on the day. The stock shows mixed signals with a bullish technical outlook from moving averages but neutral oscillators. Recent financials reveal a net income margin of -3.54% for 2026, though revenue remains stable near $4.6 trillion. Positive developments include the launch of ORZEYFUL for narcolepsy and FDA priority review for zasocitinib, highlighting a robust pipeline. Cash flow improved to $209.8 billion in 2026 from a negative position in 2025.

Outlook: TAK's strong analyst support (83% buy ratings) and promising drug pipeline offer growth potential, but profitability concerns and high P/E of 51.56 pose risks. Investors should weigh pipeline successes against current negative margins and elevated valuation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Republic Services Inc. Common Stock

Republic Services Inc. is a waste management company that provides non-hazardous solid waste collection, transfer, disposal, and recycling services across North America.

Read more on RSG →

About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.

Read more on TAK →